Entry inhibitors in the treatment of HIV-1 infection.

Infection of target cells by HIV is a complex, multi-stage process involving attachment to host cells and CD4 binding, coreceptor binding, and membrane fusion. Drugs that block HIV entry are collectively known as entry inhibitors, but comprise a complex group of drugs with multiple mechanisms of action depending on the stage of the entry process at which they act. Two entry inhibitors, maraviroc and enfuvirtide, have been approved for the treatment of HIV-1 infection, and a number of agents are in development. This review covers the entry inhibitors and their use in the management of HIV-1 infection. This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol 85, issue 1, 2010.

[1]  T. Matthews,et al.  Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus , 2007, Proceedings of the National Academy of Sciences.

[2]  Stephen C. Peiper,et al.  Identification of CXCR4 Domains That Support Coreceptor and Chemokine Receptor Functions , 1999, Journal of Virology.

[3]  Bette Korber,et al.  Structure of a V3-Containing HIV-1 gp120 Core , 2005, Science.

[4]  R. Chaisson,et al.  Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.

[5]  Dominique Schols,et al.  Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection , 2004, Journal of acquired immune deficiency syndromes.

[6]  Zheng Yang,et al.  A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  C. Broder,et al.  Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Lachowicz,et al.  Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonis , 2004, Journal of medicinal chemistry.

[9]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[10]  R. Koup,et al.  Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. , 1995, AIDS research and human retroviruses.

[11]  B. Olde,et al.  Coevolution of RANTES Sensitivity and Mode of CCR5 Receptor Use by Human Immunodeficiency Virus Type 1 of the R5 Phenotype , 2004, Journal of Virology.

[12]  D. Kuritzkes,et al.  Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. , 2004, The Journal of infectious diseases.

[13]  Jay Rappaport,et al.  32 bp CCR-5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes , 1997, The Lancet.

[14]  G. Ciaramella,et al.  Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry , 2006, Journal of Virology.

[15]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[16]  A. Otaka,et al.  Structure-activity relationships of an anti-HIV peptide, T22. , 1994, Biochemical and biophysical research communications.

[17]  M. Lederman,et al.  Chemokine Analogues Show Suitable Stability for Development as Microbicides , 2008, Journal of acquired immune deficiency syndromes.

[18]  H. Schuitemaker,et al.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.

[19]  Shibo Jiang,et al.  Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains , 2008, Proceedings of the National Academy of Sciences.

[20]  C. Mackay,et al.  Interaction of Chemokine Receptor CCR5 with its Ligands: Multiple Domains for HIV-1 gp120 Binding and a Single Domain for Chemokine Binding , 1997, The Journal of experimental medicine.

[21]  Reed J. Harris,et al.  Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. , 1990, The Journal of biological chemistry.

[22]  Steven M. Wolinsky,et al.  The role of a mutant CCR5 allele in HIV–1 transmission and disease progression , 1996, Nature Medicine.

[23]  Robert Blumenthal,et al.  Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Gorlin,et al.  Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease , 2003, Nature Genetics.

[25]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[26]  Q. Sattentau,et al.  A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells , 1992, Journal of virology.

[27]  Don C. Wiley,et al.  Structure of an unliganded simian immunodeficiency virus gp120 core , 2005, Nature.

[28]  Bernhard Moser,et al.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 , 1996, Nature.

[29]  N. Graham,et al.  HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. , 2006, The Journal of infectious diseases.

[30]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[31]  R. Doms,et al.  Safe use of the CXCR4 inhibitor ALX40-4C in humans. , 2001, AIDS research and human retroviruses.

[32]  J. Sodroski,et al.  Soluble CD4 and CD4-Mimetic Compounds Inhibit HIV-1 Infection by Induction of a Short-Lived Activated State , 2009, PLoS pathogens.

[33]  H. Schuitemaker,et al.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule , 1992, Journal of virology.

[34]  D. Pillay,et al.  Emergence and Evolution of Enfuvirtide Resistance following Long-Term Therapy Involves Heptad Repeat 2 Mutations within gp41 , 2005, Antimicrobial Agents and Chemotherapy.

[35]  Martin S. Hirsch,et al.  Strong in Vitro Synergy Between the Fusion Inhibitor T‐20 and the CXCR4 Blocker AMD‐3100 , 2000, Journal of acquired immune deficiency syndromes.

[36]  R. Doms,et al.  HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide , 2009, Journal of Virology.

[37]  J. Lifson,et al.  Distribution and three-dimensional structure of AIDS virus envelope spikes , 2006, Nature.

[38]  John P. Moore,et al.  HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. , 2007, Virology.

[39]  A. Trkola,et al.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.

[40]  Kenneth A. Taylor,et al.  Cryoelectron Tomography of HIV-1 Envelope Spikes: Further Evidence for Tripod-Like Legs , 2008, PLoS pathogens.

[41]  John P. Moore,et al.  Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusion , 2005, Nature.

[42]  Hans Wolf,et al.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS , 1986, Cell.

[43]  J. Albert,et al.  Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. , 2005, The Journal of general virology.

[44]  E. Hunter,et al.  Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity , 1992, Journal of virology.

[45]  J. Sodroski,et al.  Stoichiometry of Envelope Glycoprotein Trimers in the Entry of Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.

[46]  William C. Olson,et al.  Mapping the Determinants of the CCR5 Amino-Terminal Sulfopeptide Interaction with Soluble Human Immunodeficiency Virus Type 1 gp120-CD4 Complexes , 2001, Journal of Virology.

[47]  J. Kappes,et al.  Sensitivity of Human Immunodeficiency Virus Type 1 to the Fusion Inhibitor T-20 Is Modulated by Coreceptor Specificity Defined by the V3 Loop of gp120 , 2000, Journal of Virology.

[48]  H. Schuitemaker,et al.  Sensitivity of Primary R5 HIV-1 to Inhibition by Rantes Correlates with Sensitivity to Small-Molecule R5 Inhibitors , 2005, Antiviral Therapy.

[49]  Mike Youle,et al.  Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir , 2006, Journal of Virology.

[50]  J. Mascola,et al.  Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel , 2000, AIDS.

[51]  B. Margolin,et al.  V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability , 1993, Journal of virology.

[52]  Masahiko Kuroda,et al.  Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development , 1998, Nature.

[53]  A Muñoz,et al.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.

[54]  T. Oas,et al.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Carlos Toro,et al.  Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV‐infected patients experiencing prolonged virologic failure , 2004, Journal of medical virology.

[56]  A. Trkola,et al.  Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 , 2001, Journal of Virology.

[57]  H. Schuitemaker,et al.  Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. , 2003, The Journal of infectious diseases.

[58]  Emmanuel G. Cormier,et al.  The Crown and Stem of the V3 Loop Play Distinct Roles in Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Interactions with the CCR5 Coreceptor , 2002, Journal of Virology.

[59]  C. Broder,et al.  Mutagenesis of CXCR4 Identifies Important Domains for Human Immunodeficiency Virus Type 1 X4 Isolate Envelope-Mediated Membrane Fusion and Virus Entry and Reveals Cryptic Coreceptor Activity for R5 Isolates , 1999, Journal of Virology.

[60]  J. Kappes,et al.  Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy , 2002, Antimicrobial Agents and Chemotherapy.

[61]  T. Chun,et al.  Biochemical and Biological Characterization of a Dodecameric CD4-Ig Fusion Protein , 2002, The Journal of Biological Chemistry.

[62]  R. Siliciano,et al.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.

[63]  R. Redfield,et al.  Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. , 2008, The Journal of infectious diseases.

[64]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[65]  Peter D. Kwong,et al.  Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4 , 2007, Science.

[66]  M. Hughes,et al.  Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. , 2007, The Journal of infectious diseases.

[67]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[68]  B. Wood,et al.  Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte–colony‐stimulating factor by single‐dose administration of AMD3100, a CXCR4 antagonist , 2005, Transfusion.

[69]  Q. Sattentau,et al.  Human Immunodeficiency Virus Type 1 Attachment to HeLa CD4 Cells Is CD4 Independent and gp120 Dependent and Requires Cell Surface Heparans , 1998, Journal of Virology.

[70]  M. Polis,et al.  Drug interactions in patients infected with human immunodeficiency virus. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  J. Albert,et al.  MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection , 1994, Journal of clinical microbiology.

[72]  T. Matthews,et al.  A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. , 1993, AIDS research and human retroviruses.

[73]  M. Baba,et al.  Isolation and Characterization of Human Immunodeficiency Virus Type 1 Resistant to the Small-Molecule CCR5 Antagonist TAK-652 , 2006, Antimicrobial Agents and Chemotherapy.

[74]  E. Fenyö,et al.  In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression , 1997, Nature Medicine.

[75]  Ying Sun,et al.  The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.

[76]  John P. Moore,et al.  Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249 , 2008, Proceedings of the National Academy of Sciences.

[77]  M. Locati,et al.  HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation. , 1997, Virology.

[78]  J. Margolick,et al.  Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study , 2000, AIDS.

[79]  J. Sodroski,et al.  Identification of Conserved and Variable Structures in the Human Immunodeficiency Virus gp120 Glycoprotein of Importance for CXCR4 Binding , 2002, Journal of Virology.

[80]  J. Howe,et al.  Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. , 2008, Virology.

[81]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[82]  N. Graham,et al.  Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy , 2007, AIDS.

[83]  J. Park,et al.  Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects , 2007, Antimicrobial Agents and Chemotherapy.

[84]  R. Doms,et al.  Identification of gp120 Binding Sites on CXCR4 by Using CD4-Independent Human Immunodeficiency Virus Type 2 Env Proteins , 2003, Journal of Virology.

[85]  Shibo Jiang,et al.  Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors , 2009, AIDS.

[86]  R. Connor,et al.  Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.

[87]  Douglas S Kwon,et al.  DC-SIGN, a Dendritic Cell–Specific HIV-1-Binding Protein that Enhances trans-Infection of T Cells , 2000, Cell.

[88]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[89]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[90]  P. Rose,et al.  Adaptive Mutations in the V3 Loop of gp120 Enhance Fusogenicity of Human Immunodeficiency Virus Type 1 and Enable Use of a CCR5 Coreceptor That Lacks the Amino-Terminal Sulfated Region , 2001, Journal of Virology.

[91]  Michael J Silverberg,et al.  Effect of early versus deferred antiretroviral therapy for HIV on survival. , 2009, The New England journal of medicine.

[92]  Kenneth A. Taylor,et al.  Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[93]  T. Oas,et al.  Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[94]  Kouji Matsushima,et al.  The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract , 1998, Nature.

[95]  Anthony S. Fauci,et al.  AIDS: Re-emergence of HIV after stopping therapy , 1999, Nature.

[96]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[97]  Joseph Sodroski,et al.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 , 1996, Nature.

[98]  Jun Zhang,et al.  CCR5 Small-Molecule Antagonists and Monoclonal Antibodies Exert Potent Synergistic Antiviral Effects by Cobinding to the Receptor , 2007, Molecular Pharmacology.

[99]  Cassandra B. Jabara,et al.  Enfuvirtide Resistance Mutations: Impact on Human Immunodeficiency Virus Envelope Function, Entry Inhibitor Sensitivity, and Virus Neutralization , 2005, Journal of Virology.

[100]  C. Broder,et al.  CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.

[101]  J. Word,et al.  Virologic Failure in Therapy-Naïve Subjects on Aplaviroc plus Lopinavir-Ritonavir: Detection of Aplaviroc Resistance Requires Clonal Analysis of Envelope , 2008, Antimicrobial Agents and Chemotherapy.

[102]  J. Sodroski,et al.  Selective Interactions of Polyanions with Basic Surfaces on Human Immunodeficiency Virus Type 1 gp120 , 2000, Journal of Virology.

[103]  J. Sodroski,et al.  Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. , 2006, Biochemistry.

[104]  Wei Huang,et al.  Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. , 2007, The Journal of infectious diseases.

[105]  Yuetsu Tanaka,et al.  The Novel CXCR4 Antagonist KRH-3955 Is an Orally Bioavailable and Extremely Potent Inhibitor of Human Immunodeficiency Virus Type 1 Infection: Comparative Studies with AMD3100 , 2009, Antimicrobial Agents and Chemotherapy.

[106]  D. Ho,et al.  In Vivo Distribution of the Human Immunodeficiency Virus/Simian Immunodeficiency Virus Coreceptors: CXCR4, CCR3, and CCR5 , 1998, Journal of Virology.

[107]  D. Ho,et al.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[108]  R. Lal,et al.  CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage. , 1998, Virology.

[109]  G. Melikyan,et al.  HIV Enters Cells via Endocytosis and Dynamin-Dependent Fusion with Endosomes , 2009, Cell.

[110]  Shibo Jiang,et al.  HIV-1 inhibition by a peptide , 1993, Nature.

[111]  Y. Cao,et al.  HIV-1 drug resistance in newly infected individuals. , 1999, JAMA.

[112]  S. Hammer,et al.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. , 1996, The New England journal of medicine.

[113]  Pascal Poignard,et al.  Highly Potent RANTES Analogues either Prevent CCR5-Using Human Immunodeficiency Virus Type 1 Infection In Vivo or Rapidly Select for CXCR4-Using Variants , 1999, Journal of Virology.

[114]  K. Kabeya,et al.  Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140) , 2007, Antimicrobial Agents and Chemotherapy.

[115]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[116]  T. Schwartz,et al.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.

[117]  Joel E Gallant,et al.  A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy , 2003, AIDS.

[118]  H. Guy,et al.  Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct but Overlapping Structures Involved in Chemokine and Coreceptor Function* , 1999, The Journal of Biological Chemistry.

[119]  R. Davey,et al.  Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults , 2005, AIDS.

[120]  Michael S. Kay,et al.  Potent D-peptide inhibitors of HIV-1 entry , 2007, Proceedings of the National Academy of Sciences.

[121]  Marc Parmentier,et al.  The Second Extracellular Loop of CCR5 Is the Major Determinant of Ligand Specificity* , 1997, The Journal of Biological Chemistry.

[122]  J. Sodroski,et al.  Localized Changes in the gp120 Envelope Glycoprotein Confer Resistance to Human Immunodeficiency Virus Entry Inhibitors BMS-806 and #155 , 2004, Journal of Virology.

[123]  H. Schuitemaker,et al.  Association between CCR5 Genotype and the Clinical Course of HIV-1 Infection , 1997, Annals of Internal Medicine.

[124]  D. Richman,et al.  Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine , 2003, AIDS.

[125]  James E. Robinson,et al.  Envelope Conformational Changes Induced by Human Immunodeficiency Virus Type 1 Attachment Inhibitors Prevent CD4 Binding and Downstream Entry Events , 2006, Journal of Virology.

[126]  R. Doms,et al.  Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. , 2009, Virology.

[127]  Michael Greenberg,et al.  Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes , 2004, Nature Reviews Drug Discovery.

[128]  D. Richman,et al.  The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. , 1994, The Journal of infectious diseases.

[129]  J. Goudsmit,et al.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution , 1992, Journal of virology.

[130]  Marc Parmentier,et al.  A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.

[131]  M. Baba,et al.  T134, a Small-Molecule CXCR4 Inhibitor, Has No Cross-Drug Resistance with AMD3100, a CXCR4 Antagonist with a Different Structure , 1999, Journal of Virology.

[132]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[133]  X Zhang,et al.  A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. , 1998, Biochemical and biophysical research communications.

[134]  G. D. Miralles,et al.  T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. , 2005, The Journal of infectious diseases.

[135]  A. Lazzarin,et al.  Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations , 2008, Journal of medical virology.

[136]  T L Hoffman,et al.  Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[137]  M. Hirsch,et al.  Discovery and Characterization of Vicriviroc (SCH 417690), a CCR5 Antagonist with Potent Activity against Human Immunodeficiency Virus Type 1 , 2005, Antimicrobial Agents and Chemotherapy.

[138]  S. Yerly,et al.  Transmission of antiretroviral-drug-resistant HIV-1 variants , 1999, The Lancet.

[139]  P. Volberding,et al.  The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. , 2002, AIDS research and human retroviruses.

[140]  A. Trkola,et al.  Estimating the Stoichiometry of Human Immunodeficiency Virus Entry , 2008, Journal of Virology.

[141]  M. Lederman,et al.  Prevention of Vaginal SHIV Transmission in Rhesus Macaques Through Inhibition of CCR5 , 2004, Science.

[142]  Y. Iwasaki,et al.  Efficient inhibition of SDF‐1α‐mediated chemotaxis and HIV‐1 infection by novel CXCR4 antagonists , 2009, Cancer science.

[143]  M. Goldsmith,et al.  Multiple Extracellular Elements of CCR5 and HIV-1 Entry: Dissociation from Response to Chemokines , 1996, Science.

[144]  Marc Parmentier,et al.  Regions in β-Chemokine Receptors CCR5 and CCR2b That Determine HIV-1 Cofactor Specificity , 1996, Cell.

[145]  A. Trkola,et al.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[146]  John P. Moore,et al.  Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41 , 2009, Proceedings of the National Academy of Sciences.

[147]  D. Missé,et al.  Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes , 2003, Nature Biotechnology.

[148]  H. Sheppard,et al.  The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression , 1997, Nature Medicine.

[149]  William C. Olson,et al.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.

[150]  David A. Price,et al.  Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity , 2005, Antimicrobial Agents and Chemotherapy.

[151]  J. Sodroski,et al.  Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[152]  Steven G. Deeks,et al.  Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility ofHuman Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors , 2007, Journal of Virology.

[153]  Hui Li,et al.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.